SCHEMBL341017

SCHEMBL341017

CC(C)C(=O)Nc1c(-c2ccccc2)cccc1C(C)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.45
MEN1 O00255 4/20 0.45
MAPT P10636 2/20 0.45
ALDH1A1 P00352 2/20 0.45
RXFP1 Q9HBX9 1/20 0.45
CXCL8 P10145 1/20 0.45
ADORA1 P30542 3/20 0.43
LMNA P02545 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
HTT P42858 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
MMP1 P03956 1/20 0.42
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
MMP8 P22894 1/20 0.42
MMP12 P39900 1/20 0.42
MMP13 P45452 1/20 0.42
MMP14 P50281 1/20 0.42
MMP16 P51512 1/20 0.42
PTGS2 P35354 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL339362 0.87 CXCL8 (0.46) KMT2AMEN1MAPTALDH1A1CXCL8
SCHEMBL338541 0.83 MAPT (0.43) KMT2AMEN1MAPTALDH1A1CXCL8
SCHEMBL341491 0.81 SOAT1 (0.46) KMT2AMEN1MAPTALDH1A1CXCL8
SCHEMBL341352 0.79 LMNA (0.50) KMT2AMEN1MAPTALDH1A1RXFP1
SCHEMBL18061111 0.78 TAAR1 (0.51) KMT2AMEN1ALDH1A1LMNASMN1; SMN2
SCHEMBL2393839 0.78 PTGS2 (0.56) KMT2AMEN1MAPTCXCL8LMNA
Biphenyl SCHEMBL7876282 0.76 PTGS2 (0.58) KMT2AMEN1MAPTCXCL8LMNA
SCHEMBL11766705 0.75 PPARG (0.49) KMT2AMEN1MAPTALDH1A1CXCL8
SCHEMBL368609 0.75 PTGS2 (0.43) PTGS2
SCHEMBL10781115 0.74 PTGS2 (0.53) KMT2AMEN1MAPTCXCL8LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181175-B2 Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid Zhejiang Jiuzhous Pharmaceutical Co., Ltd. (CN) 2015-11-10 US disclosed
EP-2387558-B1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARM CO LTD (CN) 2014-08-27 EP disclosed
US-20140179947-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) 2014-06-26 US disclosed
US-8703990-B2 Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid Zhejiang Jiuzhous Pharmaceutical Co., Ltd. (CN) 2014-04-22 US disclosed
US-20120016151-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID NOVARTIS AG (CH) 2012-01-19 US disclosed
EP-2387558-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (CN) 2011-11-23 EP disclosed
US-20110253230-A1 Temperature Sensitive Valve Having Shape Memory Actuator OMNITEK PARTNERS LLC (US) 2011-10-20 US disclosed
WO-2010081410-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) 2010-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179947-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID DNPEP, MME, DPP7 KMT2A 2149/4885MEN1 3083/4885MAPT 1676/4885
US-20120016151-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID DNPEP, MME, DPP7 KMT2A 2149/4885MEN1 3083/4885MAPT 1676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.